Pfizer to Double Down Success of mRNA for Vaccines Outside of Covid

According to a Wall Street Journal report, the U.S.-based drugmaker Pfizer (PFE) could soon be taking its impressive mRNA technology to the wider world of medicine.

Teaming up with German drug developer, BioNTech (BTNX), Pfizer was able to deliver the first approved vaccine to market, to fight the COVID-19 virus, using its mRNA technology, which the company now says it will use to make new vaccines for other viruses.

With the sparkling success of Pfizer’s mRNA vaccine, which proved to be 95% effective at preventing COVID-19, in late-stage trials, the company says it’s ready to set out on its own and consider mRNA use in other areas of medicine beyond vaccines, which naturally will attract billions of dollars in investments.

It’s not yet known which other viruses or illnesses Pfizer will target to treat first, outside of COVID-19, using its mRNA technology, but you can believe healthcare investors are keeping a closer eye on the drugmaker’s next move.

Originally published by CNBC.com

Add Comment

Market Overview

Leave a Reply


Your email address will not be published. Required fields are marked *

*